Lung Cancer News and Research

Latest Lung Cancer News and Research

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

25 May 2012

Researchers identify genetic marker linked with smoking quantity in African Americans

In a step toward understanding possible genetic differences in smoking behaviors, a team of researchers co-led by SRI International has identified a genetic marker associated with smoking quantity in people of African ancestry.

23 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

22 May 2012

Tuberculosis independently predicts death from lung cancer in the elderly

Tuberculosis independently predicts death from lung cancer in the elderly, according to a new study from researchers in Hong Kong.

21 May 2012

Review examines benefits and harms of LDCT screening for lung cancer

Peter B. Bach, M.D., of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a systematic review to examine the evidence regarding the benefits and harms of low-dose computerized tomography (LDCT) screening for lung cancer, which is the leading cause of cancer death. "Most patients are diagnosed with advanced disease, resulting in a very low 5-year survival rate," the authors write.

21 May 2012

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.

19 May 2012

Personal genetic test results does not drive overuse of expensive medical care

People have increasing opportunities to participate in genetic testing that can indicate their range of risk for developing a disease. Receiving these results does not appreciably drive up or diminish test recipients' demand for potentially costly follow-up health services, according to a study performed by researchers at the National Institutes of Health and colleagues at other institutions.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.

19 May 2012

Promising updates in quest for early detection and treatments for lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month.

18 May 2012

Personal genetic test results don't drive overuse of expensive medical care

People have more and more chances to participate in genetic testing that can indicate their range of risk for developing a disease. Receiving these results does not appreciably drive up- or diminish-test recipients' demand for potentially costly follow-up health services, according to a new study in the May 17, 2012 early online issue of Genetics in Medicine.

18 May 2012

RAL proteins linked with aggressive cancer characteristics in human tumors

We have known for years that when the proteins RalA and RalB are present, cells in dishes copy toward aggressive forms of cancer. However, until this week, no study had explored the effects of RAL proteins in human cancers - an essential step on the path to developing drugs to target these proteins.

18 May 2012

CHOP researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.

17 May 2012

First trial to investigate new drug combination for NSCLC

Cancer Research UK's Drug Development Office has opened the first trial of a new drug combination in patients with advanced solid tumours and in a subset of patients who have non-small cell lung cancer. This trial will combine two compounds that aim to starve the tumours while simultaneously blocking cancer cell growth.

17 May 2012

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.

17 May 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.

17 May 2012

Molecular biomarkers in the lungs may be an additional predictive technique for cancer screening

The most recent research released in June's Journal of Thoracic Oncology says molecular biomarkers in the tissue and fluid lining the lungs might be an additional predictive technique for lung cancer screening.

16 May 2012

Better understanding of new T-size descriptors on adjuvant chemotherapy effect needed

The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer.

16 May 2012

VATS plays a valuable role in lung cancer screening program

The most recent research released in June's Journal of Thoracic Oncology says video assisted thoracic surgery (VATS) is a valuable tool in managing lesions detected in a lung cancer screening program.

16 May 2012

Lung Cancer News and Research

Latest Lung Cancer News and Research

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

Researchers identify genetic marker linked with smoking quantity in African Americans

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Tuberculosis independently predicts death from lung cancer in the elderly

Review examines benefits and harms of LDCT screening for lung cancer

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

Personal genetic test results does not drive overuse of expensive medical care

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Promising updates in quest for early detection and treatments for lung cancer

Personal genetic test results don't drive overuse of expensive medical care

RAL proteins linked with aggressive cancer characteristics in human tumors

CHOP researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma

First trial to investigate new drug combination for NSCLC

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Molecular biomarkers in the lungs may be an additional predictive technique for cancer screening

Better understanding of new T-size descriptors on adjuvant chemotherapy effect needed

VATS plays a valuable role in lung cancer screening program

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in